# **Special Issue**

# Antibacterial, Antibiofilm and Anti-virulence Activity Research of Both Natural and Synthetic Products

# Message from the Guest Editor

Antimicrobial resistance is becoming a global public health treat. The excessive use of traditional antibiotics has resulted in the emergence of multidrug resistance of microorganisms. Despite intensive efforts searching for new antimicrobial agents, there are few active candidates, and new anti-infectives that act through different mechanisms of action are needed. A promising alternative strategy to treat infections caused by MDR bacteria is antivirulence therapy, which is based on the development of drugs able to specifically inhibit virulence factors. The aim of this Issue is to present a collection of manuscripts that explore newly discovered antibacterial agents as well as their mode of action in bacteria. Potential topics may include but are not limited to:

- Discovery and/or molecular mechanisms of novel compounds with bactericidal or bacteriostatic activity
- Discovery and/or molecular mechanisms of novel compounds with activity against bacterial and/or fungal biofilm

**Keywords:** antimicrobial agent; antibiofilm agent; synergy between new antimicrobial products and conventional antibiotics

#### **Guest Editor**

Dr. Eliana De Gregorio

Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy

### Deadline for manuscript submissions

closed (31 October 2021)



an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



mdpi.com/si/44511

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

#### Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

#### **Author Benefits**

# **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

# **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

